FMP
Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
6.65 USD
-0.18 (-2.71%)
ENTA Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
-78.76M
-103.15M
-84.78M
-70M
Net Income
-116.05M
-133.82M
-121.75M
-79M
Depreciation & Amortization
2.34M
2.37M
2.97M
3.33M
Deferred Income Taxes
0
-10.55M
0
345k
Stock Based Compensation
26.8M
28.22M
26.97M
20.99M
Change in Working Capital
7.13M
8.02M
6.79M
-13.69M
Accounts Receivable
973k
9.42M
3.26M
-84k
Inventory
0
0
0
0
Accounts Payable
-414k
-1.15M
-4.63M
3.77M
Other Working Capital
6.57M
-243k
8.16M
-17.38M
Other Non-Cash Items
1.02M
2.6M
242k
-1.98M
CF from Investing Activities
58.23M
-53.58M
54.9M
36.99M
Investments in Property, Plant & Equipment
-17.95M
-9.06M
-2.13M
-750k
Net Acquisitions
0
44.52M
-54.9M
-37.74M
Investment Purchases
-307.28M
-373.39M
-171.45M
-307.35M
Sales/Maturities of Investments
383.46M
328.87M
228.47M
345.09M
Other Investing Activites
0
-44.52M
54.9M
37.74M
CF from Financing Activities
-27.63M
198.13M
20.03M
3.08M
Debt Repayment
-27.48M
-199.68M
0
0
Common Stock Issued
0
2.21M
21.26M
3.61M
Common Stock Repurchased
0
0
-1.23M
-534k
Dividends Paid
0
0
0
0
Other Financing Activites
-147k
198.13M
20.03M
3.08M
Free Cash Flow
-96.71M
-112.21M
-86.91M
-70.75M
Operating Cash Flow
-78.76M
-103.15M
-84.78M
-70M
Capital Expenditures
-17.95M
-9.06M
-2.13M
-750k
Cash at Beginning of Period
89.36M
47.96M
57.81M
87.74M
Cash at End of Period
41.2M
89.36M
47.96M
57.81M
Net Change In Cash
-48.16M
41.39M
-9.85M
-29.93M
All figures are in USD.
